• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一个用于检测临床试验中不良事件漏报的开源 R 包:IMPALA(Inter coMPany quALity Analytics)联盟的实现和验证。

An Open-Source R Package for Detection of Adverse Events Under-Reporting in Clinical Trials: Implementation and Validation by the IMPALA (Inter coMPany quALity Analytics) Consortium.

机构信息

F. Hoffmann-La Roche AG, 4070, Basel, Switzerland.

Merck & Co., Inc., Rahway, NJ, 07065, USA.

出版信息

Ther Innov Regul Sci. 2024 Jul;58(4):591-599. doi: 10.1007/s43441-024-00631-8. Epub 2024 Apr 2.

DOI:10.1007/s43441-024-00631-8
PMID:38564178
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11169048/
Abstract

Accurate and timely reporting of adverse events (AEs) in clinical trials is crucial to ensuring data integrity and patient safety. However, AE under-reporting remains a challenge, often highlighted in Good Clinical Practice (GCP) audits and inspections. Traditional detection methods, such as on-site investigator audits via manual source data verification (SDV), have limitations. Addressing this, the open-source R package {simaerep} was developed to facilitate rapid, comprehensive, and near-real-time detection of AE under-reporting at each clinical trial site. This package leverages patient-level AE and visit data for its analyses. To validate its efficacy, three member companies from the Inter coMPany quALity Analytics (IMPALA) consortium independently assessed the package. Results showed that {simaerep} consistently and effectively identified AE under-reporting across all three companies, particularly when there were significant differences in AE rates between compliant and non-compliant sites. Furthermore, {simaerep}'s detection rates surpassed heuristic methods, and it identified 50% of all detectable sites as early as 25% into the designated study duration. The open-source package can be embedded into audits to enable fast, holistic, and repeatable quality oversight of clinical trials.

摘要

准确、及时地报告临床试验中的不良事件(AEs)对于确保数据完整性和患者安全至关重要。然而,不良事件漏报仍然是一个挑战,这在良好临床规范(GCP)审核和检查中经常被强调。传统的检测方法,如通过手动源数据验证(SDV)进行现场研究者审核,存在局限性。为了解决这个问题,开发了开源 R 包 {simaerep},以促进在每个临床试验现场快速、全面和近乎实时地检测不良事件漏报。该软件包利用患者水平的不良事件和就诊数据进行分析。为了验证其有效性,IMPALA 联盟的三个成员公司独立评估了该软件包。结果表明,{simaerep}在所有三个公司中始终如一地有效识别不良事件漏报,特别是在合规和不合规站点之间不良事件发生率存在显著差异时。此外,{simaerep}的检测率超过了启发式方法,并且它在指定研究持续时间的 25%时就已经识别出了所有可检测站点的 50%。该开源软件包可以嵌入审核中,以便对临床试验进行快速、全面和可重复的质量监督。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a24f/11169048/74838bed82db/43441_2024_631_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a24f/11169048/74838bed82db/43441_2024_631_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a24f/11169048/74838bed82db/43441_2024_631_Fig1_HTML.jpg

相似文献

1
An Open-Source R Package for Detection of Adverse Events Under-Reporting in Clinical Trials: Implementation and Validation by the IMPALA (Inter coMPany quALity Analytics) Consortium.一个用于检测临床试验中不良事件漏报的开源 R 包:IMPALA(Inter coMPany quALity Analytics)联盟的实现和验证。
Ther Innov Regul Sci. 2024 Jul;58(4):591-599. doi: 10.1007/s43441-024-00631-8. Epub 2024 Apr 2.
2
Eliciting adverse effects data from participants in clinical trials.从临床试验参与者中获取不良反应数据。
Cochrane Database Syst Rev. 2018 Jan 16;1(1):MR000039. doi: 10.1002/14651858.MR000039.pub2.
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
4
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
5
MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.马克 VCID 脑小血管联盟:一、入组、临床、液体方案。
Alzheimers Dement. 2021 Apr;17(4):704-715. doi: 10.1002/alz.12215. Epub 2021 Jan 21.
6
The measurement and monitoring of surgical adverse events.手术不良事件的测量与监测
Health Technol Assess. 2001;5(22):1-194. doi: 10.3310/hta5220.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
8
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
9
Direct-acting antivirals for chronic hepatitis C.用于慢性丙型肝炎的直接作用抗病毒药物。
Cochrane Database Syst Rev. 2017 Sep 18;9(9):CD012143. doi: 10.1002/14651858.CD012143.pub3.
10
Antidepressants for pain management in adults with chronic pain: a network meta-analysis.抗抑郁药治疗成人慢性疼痛的疼痛管理:一项网络荟萃分析。
Health Technol Assess. 2024 Oct;28(62):1-155. doi: 10.3310/MKRT2948.

引用本文的文献

1
The Adoption and Use of Artificial Intelligence and Machine Learning in Clinical Development.人工智能和机器学习在临床开发中的采用与应用
Ther Innov Regul Sci. 2025 May 29. doi: 10.1007/s43441-025-00803-0.
2
Developing a Set of AI Ethics Principles to Shape Ethical Behavior in Drug Development.制定一套人工智能伦理原则以规范药物研发中的道德行为。
Ther Innov Regul Sci. 2025 May;59(3):399-402. doi: 10.1007/s43441-025-00766-2. Epub 2025 Mar 11.

本文引用的文献

1
Statistical Modeling for Quality Risk Assessment of Clinical Trials: Follow-Up at the Era of Remote Auditing.临床试验质量风险评估的统计建模:远程审计时代的随访。
Ther Innov Regul Sci. 2022 May;56(3):433-441. doi: 10.1007/s43441-022-00388-y. Epub 2022 Mar 9.
2
Risk-Based Monitoring in Clinical Trials: Increased Adoption Throughout 2020.临床试验中的基于风险的监测:2020 年全面采用。
Ther Innov Regul Sci. 2022 May;56(3):415-422. doi: 10.1007/s43441-022-00387-z. Epub 2022 Mar 2.
3
Cross-company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group.
跨公司合作利用分析技术提高临床质量并加速药物研发:IMPALA 行业组织。
CPT Pharmacometrics Syst Pharmacol. 2021 Aug;10(8):799-803. doi: 10.1002/psp4.12677. Epub 2021 Jul 11.
4
Time-consuming and expensive data quality monitoring procedures persist in clinical trials: A national survey.临床试验中仍存在耗时且昂贵的数据质量监测程序:一项全国性调查。
Contemp Clin Trials. 2021 Apr;103:106290. doi: 10.1016/j.cct.2021.106290. Epub 2021 Jan 24.
5
Follow-up on the Use of Advanced Analytics for Clinical Quality Assurance: Bootstrap Resampling to Enhance Detection of Adverse Event Under-Reporting.临床质量保证中高级分析方法应用的随访:自助重抽样以增强不良事件漏报检测
Drug Saf. 2021 Jan;44(1):121-123. doi: 10.1007/s40264-020-01011-5. Epub 2020 Oct 4.
6
Reflection on modern methods: Revisiting the area under the ROC Curve.对现代方法的反思:重新审视 ROC 曲线下面积。
Int J Epidemiol. 2020 Aug 1;49(4):1397-1403. doi: 10.1093/ije/dyz274.
7
Enabling Data-Driven Clinical Quality Assurance: Predicting Adverse Event Reporting in Clinical Trials Using Machine Learning.利用机器学习实现数据驱动的临床质量保证:预测临床试验中的不良事件报告。
Drug Saf. 2019 Sep;42(9):1045-1053. doi: 10.1007/s40264-019-00831-4.
8
Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.科学和监管原因导致新药首次申请延迟和被 FDA 否决,2000-2012 年。
JAMA. 2014;311(4):378-84. doi: 10.1001/jama.2013.282542.
9
The characteristics of patient safety culture in Japan, Taiwan and the United States.日本、台湾地区和美国的患者安全文化特征。
BMC Health Serv Res. 2013 Jan 14;13:20. doi: 10.1186/1472-6963-13-20.
10
The Benjamini-Hochberg method in the case of discrete test statistics.离散检验统计量情形下的本雅明尼-霍赫贝格方法。
Int J Biostat. 2007;3(1):Article 11. doi: 10.2202/1557-4679.1065.